Clinical Trials Browser

Phase 1 × INDUSTRY × GSK2141795 × Clear all

NCT00920257 2017-11-13

A Phase I, Open-Label, First-Time-In-Human Study of the Oral AKT Inhibitor GSK2141795

Phase 1 Completed

BreastGynecologicLymphoid

Breast Neoplasms, Lymphoma, Neoplasms, Endometrial Neoplasms

NCT01138085 2017-11-13

Safety, Pharmacokinetics (PK) of AKT and MEK Combination

Phase 1 Completed

BreastGynecologic

Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT01266954 2017-11-09

An Open Label Study To Investigate the Pharmacokinetics and Pharmacodynamics of Repeat Escalating Doses of the Oral AKT Inhibitor GSK2141795 by 18F FDG PET Analysis in Subjects With Ovarian Cancer

Phase 1 Completed

Neoplasms